User:Mr. Ibrahem/Moxetumomab pasudotox

Moxetumomab pasudotox, sold under the brand name Lumoxiti, s a medication used to treat hairy cell leukemia (HCL). It is used when other treatments have stopped working. It is given by gradual injection into a vein.

Common side effects include swelling, nausea, headache, fever, diarrhea, liver inflammation, low platelets, and low lymphocytes. Other side effects may include capillary leak syndrome, hemolytic uremic syndrome (HUS), kidney problems, and electrolyte abnormalities. It is a monoclonal antibody which binds to CD22 connected to a cytotoxin.

Moxetumomab pasudotox was approved for medical use in the United States in 2018. While it was approved in Europe and the UK in 2021, this was withdrawn later the same year. In the United States it costs about 2,200 USD per 1 mg as of 2021.